Clinical safety explainer | Reviewed 26 October 2026
Key point: India’s Central Drugs Standard Control Organization (CDSCO) lists teneligliptin — bullous pemphigoid among its adverse-drug-reaction (ADR) notifications, with a 21 September 2026 release date. This is a drug-safety signal for clinical awareness, not evidence that every patient taking teneligliptin will develop the condition.
What does the CDSCO notification say?
On its official ADR-related notifications page, CDSCO identifies teneligliptin alongside bullous pemphigoid. The same regulator page separately lists other medicines and suspected reactions. The listing is not, by itself, a population incidence estimate, an instruction for every patient to discontinue therapy, or a statement that the drug has been banned.
Check the official CDSCO ADR notification list.
What is bullous pemphigoid?
Bullous pemphigoid is an autoimmune blistering skin disorder, usually encountered in older adults. It may present with severe itch, inflamed or urticarial plaques and later tense, fluid-filled blisters. The condition has multiple possible triggers and differential diagnoses; a blistering rash alone does not prove a medicine caused it.
In the DPP-4 inhibitor class, post-marketing reports of bullous pemphigoid are already recognised internationally. For example, an FDA-approved sitagliptin product label instructs patients to seek medical advice if blisters or erosions develop. This class-level context supports vigilance but must not be confused with a teneligliptin-specific risk estimate.
Symptoms that should prompt medical review
- New widespread or persistent itching, especially with raised red patches.
- Tense blisters on the trunk, limbs or flexural areas.
- Skin erosions after blisters rupture, particularly if painful or infected.
- Extensive blistering, fever, dehydration, or involvement of eyes or mucous membranes — seek urgent care.
Clinician checklist: suspected drug-associated blistering
| Step | Why it matters |
|---|---|
| Review all medicines | Record start dates, dose changes, OTC products and other possible triggers; do not anchor on one drug. |
| Assess severity | Extent of skin involvement, mucosal symptoms, secondary infection, fluid loss and general condition determine urgency. |
| Seek dermatology assessment | Skin biopsy, direct immunofluorescence and other tests may be needed to distinguish bullous pemphigoid from mimics. |
| Review diabetes treatment promptly | If a DPP-4 inhibitor is suspected, the treating clinician should assess withdrawal/substitution and maintain glucose control. |
| Report suspected ADR | Pharmacovigilance reporting helps characterise rare and delayed adverse reactions. |
Should patients stop teneligliptin?
Do not stop or replace prescribed diabetes medicine solely because you read this alert. Patients without symptoms should discuss individual risks with their clinician during routine follow-up. New blisters or erosions warrant prompt medical assessment; the treating clinician can decide whether to withhold a suspected drug and select an alternative while monitoring blood glucose. Severe or rapidly progressing skin reactions need urgent assessment.
What this alert does—and does not—establish
It flags a potential medicine–reaction association for pharmacovigilance. It does not quantify absolute risk, prove causation in an individual, or replace product-specific prescribing information. Evidence for one DPP-4 inhibitor must not be assumed to provide the exact incidence for another. No teneligliptin dosing recommendation is made here.
Primary references
- CDSCO: ADR notifications; teneligliptin/bullous pemphigoid entry dated 21 September 2026
- US FDA: sitagliptin prescribing label, bullous pemphigoid class warning (2023 label)
Medical information disclaimer: Educational material for healthcare awareness, not personalised diagnosis or a prescription. Seek urgent medical care for severe blistering or systemic symptoms.